96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.

Zhihong LiuQinglong JinYuexin ZhangGuozhong GongGuicheng WuLvfeng YaoXiaofeng WenZhiliang GaoYan HuangDaokun YangEnqiang ChenQing MaoShide LinJia ShangHuanyu GongLihua ZhongHuafa YinFengmei WangPeng HuQiong WuChao PanWen JiaChuan LiChang'an SunJunqi Niu Jin-Lin Hounull null

Published in: Journal of clinical and translational hepatology (2022)

TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles (NCT03903796).

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
hepatitis b virus
prognostic factors
randomized controlled trial
peritoneal dialysis
patient reported outcomes
study protocol
placebo controlled
bone regeneration
smoking cessation
replacement therapy